Academic
Publications
PRS30 Identifying the Patient Population Where Treatment of Severe Allergic Asthma with Omalizumab (XOLAIR ®) Exhibits Optimal Cost-Effectiveness in Australia

PRS30 Identifying the Patient Population Where Treatment of Severe Allergic Asthma with Omalizumab (XOLAIR ®) Exhibits Optimal Cost-Effectiveness in A

PRS30 Identifying the Patient Population Where Treatment of Severe Allergic Asthma with Omalizumab (XOLAIR ®) Exhibits Optimal Cost-Effectiveness in Australia  
BibTex | RIS | RefWorks Download
Journal: Value in Health - VALUE HEALTH , vol. 14, no. 7, pp. A492-A493, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.